Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.

Abstract:

:Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first allogenic HSCT with neutrophil engraftment. Of these 219 patients, 50 (22.8%) had DPR that was defined as relapse-free survival at day 60 after HSCT without primary platelet recovery despite neutrophil engraftment. The results of a multivariate analysis showed that a high-risk underlying disease (odds ratio [OR], 2.38; 95% confidence interval [CI], 1.04-5.48; P = .041) and human leukocyte antigen-mismatched HSCT (OR, 2.63; 95% CI, 1.28-5.43; P = .009) were associated with an increased risk of DPR. In univariate analyses, the occurrence of DPR was significantly associated with inferior overall survival, high nonrelapse mortality, and a low incidence of chronic graft-versus-host disease (GVHD), despite a comparable relapse rate. In multivariate analyses, DPR was associated with inferior overall survival (hazard ratio [HR], 2.00; 95% CI, 1.23-3.27; P = .005) and a low incidence of chronic GVHD (HR, 0.42; 95% CI, 0.22-0.78; P = .002). In conclusion, DPR was a strong predictor of shorter survival but also less frequent chronic GVHD.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Akahoshi Y,Kimura SI,Gomyo A,Hayakawa J,Tamaki M,Harada N,Kusuda M,Kameda K,Ugai T,Wada H,Ishihara Y,Kawamura K,Sakamoto K,Sato M,Terasako-Saito K,Kikuchi M,Nakasone H,Kako S,Kanda Y

doi

10.1002/hon.2427

subject

Has Abstract

pub_date

2018-02-01 00:00:00

pages

276-284

issue

1

eissn

0278-0232

issn

1099-1069

journal_volume

36

pub_type

杂志文章
  • Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process.

    abstract::Some patients with cerebriform T-cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transfo...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080406

    authors: Greer JP,Salhany KE,Cousar JB,Fields JP,King LE,Graber SE,Flexner JM,Stein RS,Collins RD

    更新日期:1990-07-01 00:00:00

  • Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

    abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2515

    authors: Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

    更新日期:2018-10-01 00:00:00

  • Improved survival of older patients with multiple myeloma in the era of novel agents.

    abstract::Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2205

    authors: Mey UJ,Leitner C,Driessen C,Cathomas R,Klingbiel D,Hitz F

    更新日期:2016-12-01 00:00:00

  • Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.

    abstract::We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but rel...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/hon.2900090411

    authors: Herbrecht R,Ortiz S,Damonte JC,Liu KL,Maloisel F,Dufour P,Bergerat JP,Oberling F

    更新日期:1991-07-01 00:00:00

  • On point in primary CNS lymphoma.

    abstract::Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2761

    authors: Tsang M,Cleveland J,Rubenstein JL

    更新日期:2020-12-01 00:00:00

  • Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.

    abstract::This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.860

    authors: Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

    更新日期:2008-12-01 00:00:00

  • Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art.

    abstract::The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2676

    authors: Albano D,Bruno A,Patti C,Micci G,Midiri M,Tarella C,Galia M

    更新日期:2020-02-01 00:00:00

  • Severe retinopathy following radiation therapy with a moderate dose for orbital mucosa-associated lymphoid tissue lymphoma.

    abstract::Mucosa-associated lymphoid tissue (MALT) lymphoma is a radiosensitive malignancy. We report on a case of severe retinopathy following radiation therapy with a moderate dose for orbital MALT lymphoma. A 69-year-old woman with orbital MALT lymphoma received definitive radiation therapy with a total dose of 36 Gy in 18 f...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2124

    authors: Hata M,Kaneko A,Tomita N,Inoue T

    更新日期:2014-12-01 00:00:00

  • Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.

    abstract::The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2811

    authors: Takahashi T,Suzuki R,Yamamoto G,Nakazawa H,Kurosawa M,Kobayashi T,Okada M,Akasaka T,Kim SW,Fukuda T,Ichinohe T,Atsuta Y,Suzumiya J

    更新日期:2020-09-26 00:00:00

  • R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.

    abstract::Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.829

    authors: Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

    更新日期:2008-03-01 00:00:00

  • Lymphomas and thyroid: Bridging the gap.

    abstract::The thyroid gland is often involved in the development of neoplastic diseases, including lymphoproliferative disorders. The aim of this paper is to provide a comprehensive overview of the multiple interactions between lymphoma and thyroid. Through an extensive research among the literature, the relationship between ly...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2504

    authors: Mancuso S,Carlisi M,Napolitano M,Siragusa S

    更新日期:2018-02-27 00:00:00

  • Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.

    abstract::Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2750

    authors: Le Bris Y,Magrangeas F,Moreau A,Chiron D,Guérin-Charbonnel C,Theisen O,Pichon O,Canioni D,Burroni B,Maisonneuve H,Thieblemont C,Oberic L,Gyan E,Pellat-Deceunynck C,Hermine O,Delfau-Larue MH,Tessoulin B,Béné MC,Minviel

    更新日期:2020-10-01 00:00:00

  • Cytogenetics and molecular genetics of childhood leukemia.

    abstract::Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199909)17:3<91::aid-hon643

    authors: Ma SK,Wan TS,Chan LC

    更新日期:1999-09-01 00:00:00

  • Large cell lymphoma with initial presentation in the bone marrow.

    abstract::This report describes 14 cases of large cell lymphoma with initial presentation as marrow involvement in the absence of peripheral lymphadenopathy. The disease affected mainly the middle-aged and elderly, with male predominance. Most patients presented with swinging fever and peripheral blood cytopenia. Reactive hemop...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100504

    authors: Wong KF,Chan JK,Ng CS,Chu YC,Li LP,Chan CH

    更新日期:1992-09-01 00:00:00

  • Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders.

    abstract::Post-transplant lymphoproliferative disorders (PTLD) derive from antigen-experienced B-cells and represent a major complication of solid organ transplantation. We characterized usage, mutation frequency and mutation pattern of immunoglobulin variable (IGV) gene rearrangements in 50 PTLD (polymorphic PTLD, n=10; diffus...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.791

    authors: Capello D,Cerri M,Muti G,Lucioni M,Oreste P,Gloghini A,Berra E,Deambrogi C,Franceschetti S,Rossi D,Alabiso O,Morra E,Rambaldi A,Carbone A,Paulli M,Gaidano G

    更新日期:2006-12-01 00:00:00

  • Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.

    abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1017

    authors: Gu K,Weisenburger DD,Fu K,Chan WC,Greiner TC,Aoun P,Smith LM,Bast M,Liu Z,Bociek RG,Bierman PJ,Armitage JO,Vose JM

    更新日期:2012-09-01 00:00:00

  • Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.

    abstract::Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2178

    authors: Bhagat P,Sachdeva MU,Sharma P,Naseem S,Ahluwalia J,Das R,Varma N,Law A,Malhotra P

    更新日期:2016-03-01 00:00:00

  • Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level.

    abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120104

    authors: Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

    更新日期:1994-01-01 00:00:00

  • Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in Hodgkin's disease.

    abstract::Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8. Recombinant human g...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900090608

    authors: Oza AM,Leahy M,Dorey E,Davis CL,Amess J,Horton M,Rohatiner AZ,Wrigley PF,Lister TA

    更新日期:1991-11-01 00:00:00

  • Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.

    abstract::Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2522

    authors: Thompson CA,Yost KJ,Maurer MJ,Allmer C,Farooq U,Habermann TM,Inwards DJ,Macon WR,Link BK,Rosenthal AC,Cerhan JR

    更新日期:2018-12-01 00:00:00

  • The burden of autoimmunity in myelodysplastic syndromes.

    abstract::The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present rev...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2423

    authors: Fozza C

    更新日期:2018-02-01 00:00:00

  • Antisense therapy for lymphomas.

    abstract::The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199702)15:1<3::aid-hon583>

    authors: Cotter FE

    更新日期:1997-02-01 00:00:00

  • Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.

    abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2775

    authors: Viviani S,Mazzocchi A,Pavoni C,Taverna F,Rossi A,Patti C,Romano A,Trentin L,Sorasio R,Guidetti A,Gottardi D,Tarella C,Cimminiello M,Zanotti R,Farina L,Ferreri AJM,Galbiati M,Corradini P,Gianni AM,Gallamini A,Ramba

    更新日期:2020-10-01 00:00:00

  • A controversial issue: could a watch-and-wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre study.

    abstract:BACKGROUND:A subset of patients with non-Hodgkin's lymphoma (NHL) with clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus without any target lesion to judge the immediate effectiveness of immediately applied additional treatment ...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(199705)15:2<53::aid-hon598

    authors: Jelić S,Frim O,Gligorijević G,Gavrilović D,Manojlović N,Jovanović V,Oprić M

    更新日期:1997-05-01 00:00:00

  • Rare mature B-cell lymphomas in children and adolescents.

    abstract::Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Bo...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2585

    authors: Woessmann W,Quintanilla-Martinez L

    更新日期:2019-06-01 00:00:00

  • CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.

    abstract::From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(199809)16:3<117::aid-hon63

    authors: Chim CS,Kwong YL,Lie AK,Lee CK,Liang R

    更新日期:1998-09-01 00:00:00

  • Intravascular lymphoma: a neoplasm of 'homeless' lymphocytes?

    abstract::Intravascular lymphoma (IVL) is an extremely rare form of non-Hodgkin lymphoma characterized by almost exclusive growth of neoplastic lymphocytes within blood vessel lumen. IVL is morphologically characterized in most instances by large cells with B-cell lineage. IVL is an aggressive and usually disseminated disease t...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.776

    authors: Ponzoni M,Ferreri AJ

    更新日期:2006-09-01 00:00:00

  • Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation.

    abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2195

    authors: Gupta A,Punatar S,Gawande J,Bagal B,Mathew L,Bhat V,Kannan S,Khattry N

    更新日期:2016-09-01 00:00:00

  • The value of EUS in combination with cytological, flow cytometry, and gene rearrangement in the diagnosis of gastrointestinal lymphoma.

    abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2298

    authors: Yu L,Chen K,Xu Y,Wang S,Liu Q,Ye Q,Ye T,Sun Y

    更新日期:2017-09-01 00:00:00

  • Establishment of a novel human B-cell line (OZ) with t(14;18)(q32;q21) and aberrant p53 expression was associated with the homozygous deletions of p15INK4B and p16INK4A genes.

    abstract::The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199708)15:3<109::aid-hon60

    authors: Nagai M,Fujita M,Ohmori M,Matsubara S,Taniwaki M,Horiike S,Tasaka T,Koeffler HP,Takahara J

    更新日期:1997-08-01 00:00:00